Altimmune Has Completed Patient Enrollment In IMPACT Phase 2B Biopsy-driven Trial Evaluating Pemvidutide In Metabolic Dysfunction-associated Steatohepatitis, Top-line Efficacy Data Expected In Q2 2025
Portfolio Pulse from Benzinga Newsdesk
Altimmune has completed patient enrollment for its Phase 2B trial of pemvidutide in treating MASH, with results expected in Q2 2025. An FDA meeting for its obesity program is set for November 2024, and the company plans to submit IND applications for additional indications in late 2024.
September 30, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altimmune has completed enrollment for its Phase 2B trial of pemvidutide in MASH, with results expected in Q2 2025. The company is also planning regulatory meetings and submissions for its obesity program and other indications.
The completion of patient enrollment in a significant trial and upcoming regulatory meetings and submissions indicate progress in Altimmune's pipeline, which is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100